57060-86-3

Basic information

• Product Name: Methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• Synonyms: 1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBOXYLIC ACID METHYL ESTER;3-ISOQUINOLINECARBOXYLIC ACID, 1,2,3,4-TETRAHYDRO-, METHYL ESTER;AKOS B020563;AKOS BB-6889;METHYL 1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLATE;ART-CHEM-BB B020563;1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid methyl ester ,95%
• CAS NO: 57060-86-3
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Mol File: 57060-86-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 298 °C at 760 mmHg
• Flash Point: 134.1 °C
• Appearance: /
• Density: 1.125 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate(57060-86-3)
• EPA Substance Registry System: Methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate(57060-86-3)

Safety Data

• Hazardous Substances Data: 57060-86-3(Hazardous Substances Data)

Usage

General Description

Methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate is a specific type of chemical compound classified within the tetrahydroisoquinoline family. It has a highly specific structure that follows its name: a cyclical arrangement with a methyl ester attached, that is derived from the isoquinoline alkaloid chemical group. While there is not much information about it, the tetrahydroisoquinoline group of compounds is notable for their presence in a variety of biological organisms and for their use in making other compounds in both pharmaceutical applications and organic chemistry research. The specific uses and properties of "Methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate", however, may vary based on the exact arrangement and attachments of its structure.

Upstream product

• 67-56-1 methanol 
• 67123-97-1 (R,S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 150-30-1 Phenylalanine 
• 144831-77-6 (S)-3-(3-cyanophenyl)-2-(naphthalene-2-sulfonamido)propanoic acid 
• 63-91-2 L-phenylalanine 

Downstream Products

• 63006-93-9 3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline 
• 27104-73-0 methyl isoquinoline-3-carboxylate 
• 74163-81-8 L-Tic-OH 
• 112794-29-3 3-(aminocarbonyl)-1,2,3,4-tetrahydroisoquinoline 
• 147557-04-8 3-aminomethyl-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

New four-component Ugi-type reaction. Synthesis of 3-methyl-1-oxo-1,3,4,6, 11,11a-hexahydro-2H-pyrazino[1,2-b]isoquinoline-3-carboxamides

A small-sized library of novel 3,4,11,11a-tetrahydro-2H-pyrazino[1,2-b] isoquinolin-1(6H)-ones is synthesized. Key synthetic step is based on a new variant of Ugi four component reaction using bifunctional keto acids, amine and isocyanide as starting mate

NATURAL KILLER CELLS

This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of IMK cells by increasing the expression of specific transcription factors associated with NK cell production.

Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox

Hydroxamic acids are outstanding zinc chelating groups that can be used to design potent and selective metalloenzyme inhibitors in various therapeutic areas. Some hydroxamic acids display a high plasma clearance resulting in poor in vivo activity, though they may be very potent compounds in vitro. We designed a 57-member library of hydroxamic acids to explore the structure-plasma stability relationships in these series and to identify which enzyme(s) and which pharmacophores are critical for plasma stability. Arylesterases and carboxylesterases were identified as the main metabolic enzymes for hydroxamic acids. Finally, we suggest structural features to be introduced or removed to improve stability. This work thus provides the first medicinal chemistry toolbox (experimental procedures and structural guidance) to assess and control the plasma stability of hydroxamic acids and realize their full potential as in vivo pharmacological probes and therapeutic agents. This study is particularly relevant to preclinical development as it allows obtaining compounds equally stable in human and rodent models.